<DOC>
	<DOCNO>NCT01440062</DOCNO>
	<brief_summary>Examination efficacy , safety tolerability vitamin D3 treatment Multiple Sclerosis ( MS ) .</brief_summary>
	<brief_title>Efficacy Vitamin D Supplementation Multiple Sclerosis ( EVIDIMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Informed consent Age 18 65 randomization Relapsingremitting MS accord revise McDonaldCriteria ( 2005 ) EDSS ≤ 6,0 Stable immunomodulatory treatment least 3 month Sufficient birth control ( PearlIndex &lt; 1 ) negative pregnancy test screening/randomization Any MScourse RRMS Treatment high dose vitamin D within 6 month prior randomization Patients receive last three month prior randomization , immunomodulatory therapy exception IFNβ1b ( Betaferon ® ) Any condition could interfere MRI study relate investigation Intolerability GdDTPA Hypersensitivity drug Colecalciferol Patients sarcoidosis Presence history nephrolithiasis Pseudohypoparathyroidism Clinically relevant dysfunction liver , bone narrow kidney define follow laboratory value : HB &lt; 8.5 g / dl WBC &lt; 2.5 / nl platelet count &lt; 100/nl Creatinine clearance CockcroftGault formula : Cl &lt; 110ml/min ( male ) Cl &lt; 95ml/min ( female ) AST / ALT &gt; 3.5 time high upper reference value bilirubin &gt; 2.0 mg / dl hypercalcaemia &gt; 2.7 mmol / l calcium / creatinine ratio urine &gt; 1 Treatment hydrochlorothiazide , digitoxin , digoxin , phenytoin , barbiturates Pregnancy lactation period Participation clinical study within 3 month time study Any medical , psychiatric condition could interfere patient 's ability understand give inform consent , comply protocol finish study rule commitment placement institution</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>